Related Experiment Video
Updated: Aug 24, 2025
10:25
Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection
Published on: June 5, 2021
4.8K
Neutralizing antibodies for SARS-CoV-2 infection
1Juan Berenguer, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Doctor Esquerdo 46, 28007 Madrid, Spain. jbb4@me.com.
Summary
Monoclonal antibodies (mAbs) are safe and effective for preventing and treating COVID-19, particularly in high-risk individuals. Further research is needed for specific groups and against new variants like Omicron.
Area of Science:
- Immunology
- Virology
- Pharmacology
Background:
- The COVID-19 pandemic spurred rapid development of monoclonal antibodies (mAbs) against SARS-CoV-2.
- Existing clinical data primarily involves unvaccinated populations and predates the Omicron variant.
Purpose of the Study:
- To evaluate the efficacy and safety of monoclonal antibodies (mAbs) for COVID-19 treatment and prevention.
- To identify limitations in current research and suggest future directions.
Main Methods:
- Review of clinical trial data on monoclonal antibody efficacy.
- Analysis of safety and effectiveness in preventing severe COVID-19 outcomes.
Main Results:
- Monoclonal antibodies (mAbs) demonstrated safety and effectiveness in preventing hospitalization and death in mild to moderate COVID-19 cases.
- mAbs were also effective in treating severe disease in seronegative patients and for COVID-19 prevention.
Conclusions:
- Monoclonal antibodies (mAbs) represent a valuable therapeutic option for COVID-19.
- Future research must investigate mAb effectiveness in diverse populations (e.g., immunosuppressed, previously infected) and against emerging SARS-CoV-2 variants.
